Chen H, Ikeda U, Shimpo M, Maeda Y, Shibuya M, Ozawa K, Shimada K
Department of Cardiology, Jichi Medical School, Tochigi, Japan.
J Cardiovasc Pharmacol. 2000 Oct;36(4):498-502. doi: 10.1097/00005344-200010000-00013.
Vascular endothelial growth factor (VEGF)-induced angiogenesis is involved in the etiology of some cardiovascular diseases. The soluble form of VEGF receptor, FLT-1 (sFLT-1), is a potent antagonist of VEGF. Therefore, we investigated whether transfection with the sFLT-1 gene could inhibit VEGF-induced angiogenesis. Human embryonic kidney (HEK)-293 cells were transfected with plasmids containing VEGF and sFLT-1 (pCMV-VEGF and pCMV-sFLT-1) by the calcium-phosphate co-precipitation method. VEGF- and/or sFLT-1-transfected HEK-293 cells were incubated for 24 h, and then conditioned medium was collected. The effects of conditioned medium on angiogenesis were tested by incorporation of [3H]thymidine into human umbilical vein endothelial cells (HUVECs). Expression of VEGF protein was determined by Western blotting. The conditioned medium from sFLT-1 gene-transfected HEK-293 cells significantly inhibited recombinant VEGF-induced increase in [3H]thymidine incorporation by HUVECs. VEGF gene-transfected HEK-293 cells secreted VEGF protein into conditioned medium. This conditioned medium increased [3H]thymidine incorporation by HUVECs, which was significantly inhibited by co-transfection of sFLT-1 gene with VEGF gene. These observations suggested that sFLT-1 gene transfer could inhibit VEGF-induced DNA synthesis of vascular endothelial cells.
血管内皮生长因子(VEGF)诱导的血管生成参与了某些心血管疾病的发病机制。VEGF受体的可溶性形式FLT-1(sFLT-1)是一种有效的VEGF拮抗剂。因此,我们研究了转染sFLT-1基因是否能抑制VEGF诱导的血管生成。采用磷酸钙共沉淀法将含有VEGF和sFLT-1的质粒(pCMV-VEGF和pCMV-sFLT-1)转染到人胚肾(HEK)-293细胞中。将转染了VEGF和/或sFLT-1的HEK-293细胞孵育24小时,然后收集条件培养基。通过将[3H]胸苷掺入人脐静脉内皮细胞(HUVECs)来测试条件培养基对血管生成的影响。通过蛋白质印迹法测定VEGF蛋白的表达。来自sFLT-1基因转染的HEK-293细胞的条件培养基显著抑制了重组VEGF诱导的HUVECs中[3H]胸苷掺入的增加。VEGF基因转染的HEK-293细胞将VEGF蛋白分泌到条件培养基中。这种条件培养基增加了HUVECs中[3H]胸苷的掺入,而sFLT-1基因与VEGF基因共转染则显著抑制了这种增加。这些观察结果表明,sFLT-1基因转移可抑制VEGF诱导的血管内皮细胞DNA合成。